KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
September 17 2019 - 8:30AM
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company
engaged in the discovery and development of proprietary prodrugs,
announced today that its president and chief executive officer,
Travis C. Mickle, Ph.D., will host one-on-one meetings with
investors at the Oppenheimer Fall Summit Focused on Specialty
Pharma & Rare Diseases being held September 23-24, 2019, at the
Parker New York Hotel.
Details of the conference are as follows:
Event: |
|
Oppenheimer Fall Summit
Focused on Specialty Pharma & Rare Diseases |
Dates: |
|
September 23-24, 2019 |
Format: |
|
One-on-One Meetings |
Location: |
|
Parker New York Hotel, New
York, NY |
The Oppenheimer Fall Summit brings together the
management teams from a select group of companies focused on
specialty pharmaceuticals and orphan and rare diseases with
investors to discuss therapeutic programs in development and recent
corporate updates. During the one-on-one meetings, Dr. Mickle
will discuss KemPharm’s recent strategic commercial partnering
transaction, its corporate growth strategy and its focus on
utilizing its proprietary LATTM (Ligand Activated Therapy) platform
technology to discover and develop improved prodrug versions of
FDA-approved drugs as well as prodrug versions of existing
compounds that may have applications for new disease
indications.
KemPharm’s prodrug product candidate pipeline is
highlighted by its co-lead clinical development candidates for the
treatment of ADHD, KP415 and KP484, which are based on a prodrug of
d-methylphenidate. On September 4th, 2019, KemPharm announced a
$493 million definitive collaboration and license agreement with an
affiliate of Gurnet Point Capital (GPC) that provides the affiliate
with exclusive worldwide rights to develop, manufacture and
commercialize KP415 and KP484.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LATTM
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT technology to generate improved prodrug versions of
FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, and stimulant use disorder. KemPharm’s co-lead
clinical development candidates for the treatment of ADHD, KP415
and KP484, are both based on a prodrug of d-methylphenidate, but
have differing duration/effect profiles. In addition, KemPharm has
received FDA approval for APADAZ®, an immediate-release combination
product containing benzhydrocodone, a prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts: Jason Rando
/ Maureen McEnroeTiberend Strategic Advisors, Inc.212-375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024